Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of ICOTYDE for Moderate to Severe Plaque Psoriasis Treatment Transcript

Core Insights - Protagonist has received FDA approval for ICOTYDE, a treatment for moderate to severe plaque psoriasis in adults and pediatric patients aged 12 and older who weigh at least 40 kilograms and are candidates for systemic therapy or phototherapy [1] Company Overview - The announcement was made during a presentation featuring key executives from Protagonist, including the President and CEO, CFO, and Clinical Development Adviser [1] Industry Context - The approval of ICOTYDE highlights the ongoing advancements in treatments for psoriasis, a condition that affects a significant number of patients and presents a substantial market opportunity for pharmaceutical companies [1]